Psoriasis and increased cardiovascular risk: cutaneous inflammation as a systemic marker-the role of IL-17 and endothelial dysfunction

Nahomy Martínez Pérez; Lizeth  Aquino Ruelas; Pablo Fermin Ramos Reyes; Viridiana  Gonzalez Romero; Maria Fernanda Felix Osuna; Elizabeth Romo López; Nicole  Villada Llaguno

doi:10.18203/issn.2455-4529.IntJResDermatol20252077

Authors

Nahomy Martínez Pérez Hospital General de Zona No. 89, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
Lizeth Aquino Ruelas Hospital General de Zona No. 89, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
Pablo Fermin Ramos Reyes Universidad Autónoma de Guadalajara, Zapopan, México
Viridiana Gonzalez Romero Universidad Autónoma de Guadalajara, Zapopan, México
Maria Fernanda Felix Osuna Universidad Autónoma de Guadalajara, Zapopan, México
Elizabeth Romo López Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Nicole Villada Llaguno Universidad Autónoma de Guadalajara, Zapopan, México

DOI:

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20252077

Keywords:

Atherosclerosis, Cytokine signalling, Cardiovascular risk, Endothelial dysfunction, Immunomodulation, Interleukin-17

Abstract

Psoriasis, a chronic immune-mediated inflammatory dermatosis, has been increasingly recognized as a systemic condition associated with elevated cardiovascular risk. Emerging evidence suggests that the persistent inflammatory state in psoriasis, driven by key cytokines such as interleukin-17 (IL-17), contributes to endothelial dysfunction and accelerated atherosclerosis, thereby predisposing affected individuals to major adverse cardiovascular events. This article explores the pathophysiological mechanisms linking cutaneous inflammation to systemic vascular impairment, with a particular focus on the role of IL-17 in promoting endothelial activation, leukocyte recruitment and plaque instability. Furthermore, we discuss the clinical implications of psoriasis as an independent risk factor for cardiovascular disease, emphasizing the importance of multidisciplinary management strategies to mitigate long-term cardiovascular morbidity in this patient population.

Metrics

Metrics Loading ...

References

Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12. DOI: https://doi.org/10.1111/jdv.13854

Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. DOI: https://doi.org/10.1056/NEJMra0804595

di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harbor Perspect Med. 2014;4(8):15354. DOI: https://doi.org/10.1101/cshperspect.a015354

Lowes MA, Suárez-Fariñas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32(1):227–55. DOI: https://doi.org/10.1146/annurev-immunol-032713-120225

Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38(1):11–27. DOI: https://doi.org/10.1007/s00281-015-0539-8

Benezeder T, Wolf P. Resolution of Plaque-Type Psoriasis: What Is Left Behind (and Reinitiates the Disease). Semin Immunopathol. 2019;41(6):633–44. DOI: https://doi.org/10.1007/s00281-019-00766-z

Boehncke W-H, Boehncke S, Tobin A-M, Kirby B. The ‘Psoriatic March’: A concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–7. DOI: https://doi.org/10.1111/j.1600-0625.2011.01261.x

Gisondi P, Bellinato F, Girolomoni G, Albanesi C. Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities. Front Pharmacol. 2020;11:787. DOI: https://doi.org/10.3389/fphar.2020.00117

Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, van Voorhees AS, et al. Psoriasis and Comorbid Diseases. J Am Acad Dermatol. 2017;76(3):377–90. DOI: https://doi.org/10.1016/j.jaad.2016.07.064

Sokolova MV, Simon D, Nas K, Zaiss MM, Luo Y, Zhao Y, et al. A Set of Serum Markers Detecting Systemic Inflammation in Psoriatic Skin, Entheseal and joint disease in the absence of c-reactive protein and its link to clinical disease manifestations. Arthritis Res Ther. 2020;22(1):26. DOI: https://doi.org/10.1186/s13075-020-2111-8

Montaudié H, Albert-Sabonnadière C, Acquacalda E, Fontas E, Danré A, Roux C, et al. Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2014;28(9):1186–91. DOI: https://doi.org/10.1111/jdv.12255

Beygi S, Lajevardi V, Abedini R. C-Reactive Protein in Psoriasis: A Review of the Literature. J Eur Acad Dermatol Venereol. 2014;28(6):700–11. DOI: https://doi.org/10.1111/jdv.12257

Garbaraviciene J, Diehl S, Varwig D, Bylaite M, Ackermann H, Ludwig RJ, et al. Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Exp Dermatol. 2009;19(8):736–41. DOI: https://doi.org/10.1111/j.1600-0625.2010.01095.x

Suárez-Fariñas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients With Moderate-To-Severe Psoriasis. J Invest Dermatol. 2012;132(11):2552–64. DOI: https://doi.org/10.1038/jid.2012.184

Mehta NN. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by -fluorodeoxyglucose positron emission tomography-computed tomography. Arch Dermatol. 2011;147(9):1031. DOI: https://doi.org/10.1001/archdermatol.2011.119

Armstrong AW, Harskamp CT, Armstrong EJ. The Association Between Psoriasis and Hypertension. J Hypertens. 2013;31(3):433–43. DOI: https://doi.org/10.1097/HJH.0b013e32835bcce1

Armstrong AW, Harskamp CT, Armstrong EJ. The Association Between Psoriasis and Obesity: A Systematic Review and Meta-Analysis of Observational Studies. Nutr Diabetes. 2012;2(12):54–4. DOI: https://doi.org/10.1038/nutd.2012.26